Biogen’s Alzheimer’s drug could cost Medicare billions of dollars a year, report finds

350382

Sumary of Biogen’s Alzheimer’s drug could cost Medicare billions of dollars a year, report finds:

  • The biotech company said it is charging $56,000 for an annual course of the new treatment, higher than the $10,000 to $25,000 price some Wall Street analysts were expecting..
  • Aduhelm will be covered under Medicare Part B, KFF said, which generally covers FDA-approved physician-administered medications..
  • “If 1 million Medicare beneficiaries receive Aduhelm, which may even be on the low end of Biogen’s expectations, spending on Aduhelm alone would exceed $57 billion dollars in a single year – far surpassing spending on all other Part B-covered drugs combined,”.
  • On a call with investors Tuesday morning, Evercore ISI analyst Umer Raffat congratulated the Massachusetts-based company on the drug’s U.S….

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close